The initial success of islet transplantation (ITx) is followed by graft dysfunction (GDF) and insulin reintroduction. Exenatide, a GLP-1 agonist, increases insulin and decreases glucagon secretion and has potential for β-cell regeneration. To improve functional islet mass, exenatide treatment was given to ITx recipients with GDF. The objective of this study was to assess metabolic and hormonal effects of exenatide in GDF. In this prospective, single-arm, nonrandomized study, 11 type 1 diabetes recipients of ITx with GDF had HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT; with/without exenatide given before test) at baseline, 3, 6, and 12 months after initiating exenatide treatment. Baseline MMTT showed postprandial hyperglycemia and hyperglucagonemia. Daily exenatide treatment resulted in improved glucose, increased amylin/insulin ratio, and decreased proinsulin/insulin ratio as assessed by MMTT. Glucagon responses remained unchanged. Exenatide administration 1 h before MMTT showed decreased glucagon and glucose at 0 min and attenuation in their postprandial rise. Time-to-peak glucose was delayed, followed by insulin, proinsulin, amylin, and C-peptide, indicating glucose-driven insulin secretion. Five subjects completed 12-month follow-up. Glucose and glucagon suppression responses after MMTT with exenatide were no longer observed. Retrospective 3-month analysis of these subjects revealed higher and sustained glucagon levels that did not suppress as profoundly with exenatide administration, associated with higher glucose levels and increased C-peptide responses. In conclusion, Exenatide suppresses the abnormal postprandial hyperglucagonemia and hyperglycemia observed in GDF. Changes in amylin and proinsulin secretion may reflect more efficient insulin processing. Different degrees of responsiveness to exenatide were identified. These may help guide the clinical management of ITx recipients.
INTRODUCTION
islet transplantation, defined as achievement of insulin independence, is generally followed by progressive graft dysfunction requiring reintroduction of exogenous insu-Islet transplantation under steroid-free immunosuppression is being evaluated as potential treatment for C-lin (6, 18, 32, 35) . By 5-year follow-up, even though ϳ80% of the patients remain C-peptide positive, only peptide-negative patients with type 1 diabetes mellitus (T1DM) with severe hypoglycemia and hypoglycemia ϳ10% maintain insulin independence (32) . Exenatide, a synthetic form of exendin-4 (a polypep-unawareness (18, 24, 32, 34) . Proven benefits are significant reduction of hypoglycemic events (6) and improved tide produced by the salivary glands of the gila monster), is a glucagon-like peptide (GLP)-1 receptor agonist (9,10) quality of life (29) . Unfortunately, the initial success of with longer half-life than endogenous GLP-1. Activation
The islet transplant procedure and immunosuppressive protocols have previously been reported (18, 22, 28) . of GLP-1 receptors results in enhanced glucose-stimulated insulin secretion, inhibition of glucagon secretion, delayed gastric emptying, and increased satiety (10, 26, Definitions 27) . In rodent models, effects include promotion of pan-Islet transplant completion is defined as the achievecreatic progenitor cell differentiation, improve β-cell ment of insulin independence after sequential islet transfunction, and life span (13, 37, 42) . Additionally, in T2DM plantation, usually observed after two islet infusions. At management, exenatide has been shown to improve gly-3 months postcompletion the best function attained after cemic control and cause weight reduction (5, 8, 14) .
islet transplantation is typically demonstrated in insulin-To improve islet graft function and possibly increase independent subjects with stable glycemic control (2) . islet mass, exenatide treatment was started in recipients Graft dysfunction is defined as C-peptide-positive of islet transplantation alone (IA) or islet after kidney subjects (>0.09 nmol/L) with fasting and/or 2-h post-(IAK) protocols (18, 22, 28) with a history of graft dysprandial capillary glucose >7.8 and >10 mmol/L, respecfunction. The objective of this study was to assess the tively, on three or more occasions over a week, or who metabolic and hormonal effects of exenatide treatment had two sequential monthly HbA1c values >6.5% (11). acutely during a mixed meal stimulation test and to see Any subject with graft dysfunction was considered eligiif these effects are sustained during prolonged exenatide ble for reintroduction of exogenous insulin and study treatment (20) . enrollment.
MATERIALS AND METHODS
Study Design (Fig. 1 
) Study Subjects
Eleven C-peptide-positive islet recipients (Table 1) (7 HbA1c, weight, insulin requirements, and 5-h mixed meal tolerance test (MMTT) without exenatide were as-females, 4 males), from the IA (n = 10) and IAK (n = 1) protocols with a median age of 48 years (range 36-sessed at 3 months postcompletion, immediately before, and at 3, 6, and 12 months after starting exenatide treat-63), were started on exenatide at a median of 1060 days (range 485-1484) after their last islet transplant and 406 ment. Following commencement of exenatide treatment, MMTT with and without exenatide was performed at days (range 93-657) after developing graft dysfunction (defined below). Protocols were IRB approved and each follow-up visit. Subjects underwent a 5-h MMTT with exenatide administration 1 h before MMTT on the signed informed consent was obtained from all subjects. 287  287  12  2  IA  48  F  933  657  630  12  3*  IA  39  M  1,401  425  388  3  4  IA  56  M  1,308  93  0  12  5  IA  63  M  976  611  611  6  6  IA  59  F  1,104  355  355  12  7* †  IA  51  M  1,060  417  417  6  8* †  IA  38  F  1,023  406  397  3  9* †  IA  54  F  1,066  408  352  3  10 †  IA  39  F  757  239  0  6  11  IAK  44  F  485  242  242  12  Median  46  1,060  406  355  6  Min  36  485  93  0  3  Max  63  1,484  657  630  12 Time of follow-up after starting exenatide where there are data available for analysis. ITx, islet transplantation; IA, islet alone; IAK, islet after kidney. *Subjects who underwent a supplemental islet infusion after 3 or 6 months of exenatide treatment. †No MMTT data available at 3 months post-ITX completion.
first visit day, then discontinued all exenatide until a 5-tection limit; 4.5% intra-and 7.6% interassay CVs, respectively). h MMTT without exenatide a day or two later.
To assess the acute metabolic effects of exenatide, Amylin (pmol/L) was measured by ELISA, proinsulin (pmol/L), and glucagon (ng/L) by radioimmunoassay the MMTT results with and without exenatide within the same follow-up visit (3, 6, or 12 months) were com-using reagents from Linco Research, Inc (St. Charles, MO). Respectively, detection limits (and intra-and in-pared.
To assess the chronic metabolic effects of exenatide terassay CVs) were: amylin 1 pmol/L (4.5% and 11.7%), proinsulin 2 pmol/L (4.1% and 7.4%), and glucagon 20 treatment, the results of the 3, 6, and 12 month MMTT performed without exenatide were compared to the base-ng/L (3.8% and 9.1%). line (pre-exenatide) MMTT.
Calculations Exenatide Treatment Regimen
Area under the curve (AUC) of MMTT from 0-300 Exenatide (Byetta, Amylin Inc.) treatment was min was calculated for all the variables (AUC glucose , started at 5 µg subcutaneously twice daily and increased AUC C-peptide , AUC insulin , AUC amylin , AUC proinsulin , AUC glucagon ) as tolerated up to a maximum dose of 30 µg/day (usuby trapezoidal approximation. The amylin/insulin and ally divided in three doses with each meal). Total daily the proinsulin/insulin ratios were assessed for all time insulin dose was reduced 30-40%; including cessation points.The mixed meal stimulation index (MMSI) was of all meal coverage coincident with exenatide adminiscalculated using the formula (33): tration and variable reduction in basal insulin coverage to avoid hypoglycemia yet maintain euglycemia. The in-MMSI = AUC C−peptide (pmol/ml) AUC glucose (mg/dl)/100 sulin dose was then adjusted to achieve fasting and preprandial glucose levels <7.8 mmol/L and postprandial glucose levels <10 mmol/L. If insulin independence was Statistical Analysis not achieved after 3 months, and the subject was eligi-For each outcome measure, a linear mixed model reble, another islet infusion was offered.
gression was fit to the data to estimate and compare mean response values corresponding to all acute and Metabolic Studies chronic assessments of interest. This method of analysis MMTT was performed after an overnight fast (8-12 generalizes linear regression techniques allowing for reh) with samples obtained at 0, 15, 30, 60, 90, 120, 180, peated observations by taking into account correlation and 300 min after ingestion of 360 ml Boost Highwithin observations from the same subject to more approtein (Novartis, Hanover NJ; 360 calories, 9 g fat, propriately estimate variances used in tests of signifi-49.5 g carbohydrate, 22.5 g protein), administered imcance. Using this approach, we can simultaneously estimediately after obtaining the 0-min sample. At each time mate differences comparing the variables obtained from point, glucose, C-peptide, insulin, proinsulin, amylin, and the baseline pre-exenatide MMTT with values at each glucagon were measured. time point postinitiation of exenatide as well as between For the MMTT with exenatide administration, an ad-3, 6, and 12 months postinitiation of exenatide while ditional blood sample, followed immediately by exenaappropriately accounting for within-subject correlation. tide injection, was performed at −60 min. Exenatide was Similarly, we can estimate differences between MMTT administered at this time to obtain its maximal concenperformed with and without exenatide at each follow-up tration (C max occurring 1-3 h after administration) and
visit. Results are expressed as means ± SE; a value of peak action (1) coinciding with the meal. p < 0.05 was considered statistically significant. Analy-Glucose and C-peptide results from MMTT persis was performed using SAS 9.1 software (SAS Instiformed 3-months postcompletion were available in tute Inc., Cary, NC, USA). seven subjects and were used for comparison.
RESULTS

Biochemical Determinations
Clinical Outcomes in Islet Transplant Recipients Serum glucose concentrations (mmol/L) were deter-With Graft Dysfunction Treated With Exenatide mined by hexokinase method. Plasma C-peptide was measured by double antibody radioimmunoassay [Diag-Of the 11 subjects followed, four subjects underwent a supplemental islet infusion under exenatide treatment nostics Products Corp., Los Angeles, CA; 0.03-1.66nmol/ L detection limit; <10% inter-and intra-assay coefficient (three after 3 months and one after 6 months of exenatide therapy; therefore, only eight patients completed 6-of variation (CV), 20% cross-reactivity with proinsulin]. Serum insulin was measured by solid phase 125 I radioim-month follow-up). The outcomes of these four subjects after supplemental infusion are not included in this re-munoassay (Diagnostics Products Corp; 20.8 pmol/L de-port. Exenatide was discontinued in two subjects; one Pre-Exenatide. After variable periods of time (678 ± 336 days), all subjects demonstrated islet graft dysfunc-developed pneumonia requiring hospitalization at 12 months, and the other had 15% weight loss by 9 months.
tion. Reintroduction of insulin had already occurred in 9 of 11 subjects (mean dose 0.15 ± 0.03 IU/kg/day; range There are no metabolic data available for these two subjects at 12 months. Five subjects completed the study up 0-0.33) and elevation of HbA1c >6.5% (a criterion for reintroduction of insulin) in two subjects. Compared to to 12 months ( Fig. 1) .
Sixty-four percent of patients developed nausea at 3-month postcompletion, there was a significant increase in HbA1c (6.5 ± 0.1, range 5.9-7.2%, p < 0.001, n = 11) any time, which was worse in the first 2 weeks of therapy, and were treated with dose adjustment and/or anti-and islet function had markedly declined, showing return to postprandial hyperglycemia, significant increase emetics as needed. No pancreatitis was observed.
Insulin independence with target A1c was achieved in 90-min glucose (p < 0.001), peak glucose (p < 0.001), and AUC glucose (p < 0.001). C-peptide responses in 4 of 11 (36%) subjects. Two subjects were insulin independent prior to exenatide treatment and sustained to MMTT did not vary as much as the glucose levels, with a resultant decrease in the MMSI (p = 0.008) (Fig. this with a reduction in HbA1c to <6.5% (17) . Two subjects were able to discontinue exogenous insulin while 2, Table 2 ). Insulin, amylin, and proinsulin responses followed those of C-peptide. Abnormal postprandial hy-on exenatide for 67 and 386 days, respectively.
perglucagonemia was observed.
Metabolic and Hormonal Responses to MMTT
Three Months Under Exenatide Treatment. Median exenatide dose was 15 µg/day (range 5-25). Weight and Three Months Post-Islet Transplant Completion. At 3month postcompletion optimal improvement in metabolic insulin requirement decreased significantly compared with pre-exenatide (decrement 2.69 ± 0.71 kg; p = 0.001 and nutritional parameters is typically observed. All subjects were insulin independent with near-normalization of and 0.05 ± 0.02 IU/kg/day; p < 0.02 for weight and insulin requirement, respectively). HbA1c levels (5.78 ± 0.12%, range 5.7-6.4). In addition, we observed near-normalization of glucose and C-peptide Chronic effects at 3 months (assessed by comparing the MMTT without exenatide at baseline and at 3 months) responses to MMTT (n = 7) ( Table 2 , Fig. 2 ). included a decrease in AUC glucose (p = 0.052), although creased but not significantly so; the combination of decreased glucose and higher C-peptide levels resulted in overall the response remained abnormal (Fig. 2 , Table  2 ). Other variables (C-peptide, insulin, and MMSI) were a significant increase in MMSI at this time point (p = 0.03) ( Fig. 2 ). There was also a persistent marked in-not significantly different to pre-exenatide. A significant increase in AUC amylin (p = 0.02) and an increase in the crease in amylin secretion, both basal amylin (p = 0.016) and AUC amylin (p = 0.02), and significantly decreased basal amylin/insulin ratio were observed. Postprandial hyperglucagonemia was still evident and essentially un-AUC proinsulin (p = 0.012), greater than that seen after 3 months of treatment. Further increase in basal amylin/ changed.
Acute effects of exenatide (assessed by comparing insulin ratio and decrease in proinsulin/insulin ratio were observed. MMTT with and without exenatide at 3 months) were dramatic, demonstrating a significant suppression in the Acute effects of exenatide (assessed by comparing MMTT with and without exenatide at 6 months) in-glucose response curve, and significantly increased time-to-peak (p < 0.01) (Fig. 3A , Table 3 ). The secre-cluded persistent significant suppression of postprandial hyperglucagonemia (Table 3) . Changes in MMSI, tory responses followed those of glucose, with a shiftto-the-right in time-to-peak C-peptide (p < 0.001), AUC glucose , AUC C-peptide , AUC insulin , AUC amylin , and AUC proinsulin were no longer significant. amylin (p < 0.01), and proinsulin (p = 0.026). There was significant suppression of the glucagon responses after
Twelve Months Under Exenatide Treatment. Median MMTT (decrease in AUC glucagon , p < 0.001).
exenatide dose was 20 µg/day (range 10-30). The mean body weight was stable. The mean insulin requirement Six Months Under Exenatide Treatment. Median exenatide dose was 15 µg/day (range 7. . Significantly was reduced compared to pre-exenatide (p = 0.019) accompanied with significantly increased HbA1c to 7.0 ± decreased HbA1c to 6.26 ± 0.14% (range 5.5-7%, diff = 0.25 ± 0.12, p < 0.001) compared to pre-exenatide was 0.1% (range 6.7-7.3, p < 0.001). Chronic effects at 12 months (assessed by comparing observed.
Chronic effects at 6 months (assessed by comparing the MMTT without exenatide at baseline and at 12 months) demonstrated an interval deterioration with re-the MMTT without exenatide at baseline and at 6 months) included persistent marked improvement in glu-current elevation of glucose responses to MMTT, increased peak glucose (p = 0.015), and increased glucose cose responses to MMTT; C-peptide levels were in AUC (Fig. 2 ). Significant increase in basal C-peptide (p = Peak C-peptide (p = 0.04) and AUC C-peptide (p = 0.03) were significantly higher in subgroup 1. 0.01) persisted compared to pre-exenatide; AUC C-peptide remained increased, but did not reach significance at this DISCUSSION time point either. The changes observed in amylin responses at 3 and 6 months were no longer seen. In con-
The peculiar pattern of islet allograft dysfunction in patients with T1DM, where C-peptide is produced but trast, the decrease in proinsulin/insulin ratio was still evident.
is inadequate to stabilize metabolic control, therefore requiring exogenous insulin, indicates a possible meta-Acute effects of exenatide (assessed by comparing MMTT with and without exenatide at 12 months) were bolic impairment of the marginal islet mass transplanted. There is increasing data on the incretin therapy efficacy markedly diminished where compared with previous time points during exenatide treatment. The marked sup-in T2DM patients (5, 8, 14) . This has generated great interest in the possible value of exenatide in preserving pression of AUC glucose and AUC glucagon responses was not observed (Fig. 4 , Table 3 ). In addition, no significant and/or improving the function of islet grafts showing progressive dysfunction in islet recipients (16, 19) . Gho-change in insulin, amylin, proinsulin, or glucagon responses compared to pre-exenatide was detected. faili et al. (19) , using hyperglycemic glucose clamps, demonstrated increased insulin secretory capacity, espe-To see if there was a difference in response between subjects, we retrospectively compared the results at 3 cially second phase insulin release, during exenatide administration. The current study examines both the acute months of five subjects that completed 12-month followup (subgroup 1) with six subjects who did not complete and chronic metabolic and hormonal effects of 12 months of exenatide treatment as assessed by the physiologic the 12-month follow-up (subgroup 2). Subgroup 2 included four subjects that received a supplemental infu-stimulus of a mixed meal. We show that chronic exenatide administration re-sion and two that developed adverse events that required cessation of exenatide. Baseline characteristics (age, dia-sulted in significant improvement in glucose responses during the MMTT at 3 and 6 months, when compared betes duration, weight, BMI, islet equivalents/kg transplanted, time to graft dysfunction, baseline MMTT data) to baseline pre-exenatide. Additionally, there was significantly increased basal amylin/insulin ratio at 3 and 6 were similar for these subgroups. Results in subgroups 1 and 2 differed significantly in metabolic and hormonal months and decreased proinsulin/insulin ratio at 6 months. These findings suggest improvement in islet function. responses to exenatide administration (Fig. 5) . The MMTT performed without exenatide administration showed de-When comparing MMTT performed with and without exenatide at the same visit, the appearance of the layed and sustained hyperglucagonemia in subgroup 1. The statistically significant decrease in AUC glucagon and glucose and glucagon response curves with exenatide was almost an inversion of those without exenatide. In-AUC glucose during MMTT with exenatide administration was similar in both subgroups, although in subgroup 1 terestingly, during the hour between exenatide administration and ingestion of the mixed meal, we observed an there was less pronounced inhibitory response to exenatide administration. Subgroup 2 demonstrated a signifi-initial decrease in both glucagon and glucose concentrations (from −60 to 0 min); the former may be responsi-cantly more profound decrease in AUC amylin (p = 0.01). ble for the latter in the absence of calorie ingestion. glucagon suppression combined with delayed gastric emptying effects. Prospective acetaminophen absorption Even in the hour following the meal ingestion, the glucose levels remain below baseline and subsequently the studies (4) during MMTT are currently under way in an attempt to better elucidate the effect of exenatide on gas-glucose peak is very delayed, likely due to continued Figure 5 . Acute metabolic and hormonal effects of exenatide administration at 3 months in subgroup 1 (left) and subgroup 2 (right). Glucose (A), C-peptide (B), glucagon (C), and amylin (D) responses to a 5-h mixed meal tolerance test with exenatide administration before the test (MMTT-Exn +; black squares, black lines) and without (MMTT-Exn −, white squares, black lines) exenatide administration before the test in the subgroup of five subjects that completed 12 month follow-up (subgroup 1). Glucose (E), C-peptide (F), glucagon (G), and amylin (H) responses to a 5-h mixed meal tolerance test with exenatide administration before the test (MMTT-Exn +; black squares, black lines) and without (MMTT-Exn −, white squares, black lines) exenatide administration before the test in the subgroup of six subjects that did not complete 12 month follow-up (subgroup 2). tric emptying. The time-to-peak glucose significantly in-basal amylin peripheral concentrations are deleterious (36) . Furthermore, the increased amylin and decreased creased and was followed by that of insulin, proinsulin, amylin, and C-peptide. This observation suggests that proinsulin concentrations may reflect more efficient insulin processing and secretion by islet β-cells after exen-insulin secretory response is glucose driven.
It has previously been demonstrated that glucagon atide treatment.
The changes observed in HbA1c levels up to 6 levels remain unchanged in response to an oral glucose tolerance test in T1DM patients, as opposed to control months are within acceptable range and are most likely related to adjustments in insulin and exenatide therapy. subjects in whom glucagon levels decrease (21) . Additionally, subjects with diabetes fail to suppress glucagon The significant increase in HbA1c levels observed at 12 months was likely secondary to the nonresponder nature levels after carbohydrate meals and have an exaggerated glucagon response to protein meals (25) or arginine in-of subgroup 1. In addition, the long interval in followup between 6 and 12 months did not allow for prompt fusions (39) . This is interesting, given that subjects with T1DM usually have normal GLP-1 and gastric inhibitory intervention and adjustment of therapy.
There are several limitations of our study. There is polypeptide (GIP) meal responses (40) . In the present study, we demonstrated that islet transplant recipients no nondiabetic control group to assess exenatide effects on mixed meal response. While it would be interesting with graft dysfunction have postprandial hyperglucagonemia before starting exenatide therapy. Acute exenatide to see if changes are similar in healthy controls, it was not a necessity in this study where subjects acted as their administration suppressed the abnormal glucagon responses and prevented hyperglycemia after MMTT.
own controls for the assessment of both the acute and chronic effects of exenatide. There is no control group At 12 months, most of the beneficial changes observed at 3 and 6 months were no longer observed. Un-of islet transplant recipients with graft dysfunction not treated with exenatide because there were insufficient fortunately, only five patients completed the 12-month follow-up; therefore, a small sample size could explain subject numbers to perform a randomized controlled study with sufficient power to produce meaningful re-this lack of response. The retrospective analysis performed at 3 months to evaluate differences in patient sults. There is no control group of nondiabetic subjects on immunosuppression because these drugs could not be responses demonstrated some marked differences in response to the medication. The tolerated doses of exena-administered to this group in the long term due to potentially adverse effects on meal responses (38) . In addi-tide also ranged widely. This suggests that there are different degrees of responsiveness to exenatide within tion, the time from graft dysfunction to initiation of exenatide was variable in all study subjects, the reason subjects that may be apparent early on. These differences may be multifactorial in nature, including islet composi-being that the drug was not commercially available until FDA approval in 2005. Lastly, different responses in in-tion, paracrine relationships between cells, specific responsiveness of each cell-type, as well as gastric empty-dividual patients may have led to an unintended bias in subject selection. A larger randomized study may help ing. The detection of responders versus nonresponders may help guide the clinical management of islet trans-clarify better the mechanisms leading to the different clinical and physiological exenatide responses in islet plant recipients in the future. Fineman et al. described that the infusion of the hu-transplant recipients. Nevertheless, these differences were already apparent at 3 months of therapy. Perhaps man amylin analog pramlintide can correct postprandial hyperglucagonemia observed in T1DM patients (15).
performing MMTT with and without exenatide administration at the time of initiation of therapy may help iden-Our patient population showed increased peripheral basal amylin/insulin ratio after exenatide treatment for 6 tify those subjects that will be responders. Measuring functional islet mass remains a major months, which may contribute to suppression of glucagon. The long-term significance of this increase in basal challenge in islet transplantation. Glucose potentiation of arginine-induced insulin secretion (GPAIS) was not peripheral amylin remains to be defined. Constant stimulation by exenatide may lead to supraphysiological performed in this group of patients (3, 31, 41) and therefore we cannot know whether increased β-cell reserve amylin secretion and this may be worse during hyperglycemia, as described by Rickels et al. (30) . Our sub-occurred in the subgroup of responders. If regeneration was to occur in islet allografts implanted ectopically jects demonstrated progressive increase in the amylin/ insulin ratio when the chronic effects of exenatide were (liver) despite multiple detrimental hits (i.e., high immunosuppressive levels and other toxins in the portal circu-assessed. There is also the remote possibility that exenatide increases amylin secretion from different sites other lation, relative hyperglycemia in the liver, possible allorejection and autoimmunity), we postulate it would take than the islets (43) . It is well known that intraislet amylin deposits (islet amyloid polypeptide-IAPP) are much longer than the 6-month follow-up available. The reasons for the deterioration in some patients over time found in T2DM patients (7) 
